The GSE1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for studying the loss-of-function effects of the GSE1 gene in a human non-small cell lung adenocarcinoma background. This product comprises a heterogeneous pool of NCI-H1975 cells harboring targeted disruption of the endogenous GSE1 locus, generated via CRISPR/Cas9-mediated gene disruption. The polyclonal format preserves population-level genetic diversity while abrogating GSE1 protein expression, enabling robust assessment of gene function without the clonal selection biases inherent to monoclonal lines. This knockout model is suitable for a wide range of biochemical, genomic, and pharmacological assays that require stable GSE1 deficiency.
The host cell line, NCI-H1975, is a well-established human lung adenocarcinoma cell line derived from a patient with non-small cell lung cancer (NSCLC). These cells harbor activating mutations in the epidermal growth factor receptor (EGFR), specifically L858R in exon 21 and T790M in exon 20, which confer sensitivity to first- and second-generation EGFR tyrosine kinase inhibitors while promoting acquired resistance through altered kinase domain conformation. NCI-H1975 cells serve as a clinically relevant model for investigating mechanisms of EGFR-targeted therapy resistance and for identifying novel therapeutic vulnerabilities in EGFR-mutant NSCLC. The tumor-derived origin of this line provides a physiologically relevant context for studying epigenetic regulatory mechanisms in lung cancer.
GSE1 encodes a scaffold protein that is an integral component of the NSL (nonspecific lethal) histone acetyltransferase complex. Within this complex, GSE1 interacts directly with the catalytic subunit KAT8/MOF and several other core subunits, including KANSL1, KANSL2, KANSL3, MCRS1, and PHF20, to facilitate acetylation of histone H4 at lysine 16 (H4K16ac). This specific epigenetic mark is critical for chromatin decompaction and transcriptional activation of a broad range of target genes, particularly housekeeping genes and MYC-regulated transcriptional programs. Additionally, GSE1-mediated NSL complex function has been linked to BRD4, a bromodomain-containing protein that recognizes acetylated histones and recruits transcriptional elongation machinery. Disruption of GSE1 impairs proper NSL complex assembly, leading to reduced H4K16ac levels and consequent dysregulation of transcriptional outputs.
In the context of NCI-H1975 cells, knockout of GSE1 provides a unique opportunity to dissect the interplay between epigenetic regulation and oncogenic signaling in EGFR-mutant lung adenocarcinoma. The loss of GSE1 is expected to compromise the NSL complex’s acetyltransferase activity, thereby diminishing H4K16ac at promoter regions of genes essential for cellular proliferation and survival. Consequently, this knockout model can be employed to investigate how histone acetylation dynamics influence EGFR-driven oncogenic programs and how epigenetic alterations contribute to drug tolerance or resistance. Furthermore, the polyclonal GSE1 knockout NCI-H1975 cells enable exploration of synthetic lethal interactions, where the genetic ablation of GSE1 may sensitize cells to specific inhibitors of parallel chromatin remodeling pathways or other cancer-relevant targets.
This product is suited for a variety of downstream applications. Researchers can perform western blotting to monitor global H4K16ac levels or use ChIP-qPCR to assess locus-specific histone modifications. RNA-seq analyses facilitate transcriptomic profiling to identify genes whose expression depends on GSE1-mediated NSL activity. Co-immunoprecipitation experiments can verify disruption of NSL complex integrity by probing for key subunits such as KAT8 and KANSL1. Functional studies, including cell proliferation and drug sensitivity assays, enable assessment of the consequences of GSE1 loss on tumor cell growth and response to EGFR inhibitors or other therapeutic agents. Screening for synthetic lethal interactions with epigenetic drugs or other targeted therapies is also a promising use case. For more details, please contact Ascent Research.
